Vesicare

Solifenacin

Clinical data
Trade names	Vesicare
AHFS/Drugs.com	Monograph
MedlinePlus	a605019
License data	US FDA: Solifenacin
Pregnancy category	AU: B3 US: C (Risk not ruled out)
Routes of administration	By mouth
ATC code	G04BD08 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	90%
Protein binding	98%
Metabolism	CYP3A4
Metabolites	Glucuronide, N-oxide, others
Biological half-life	45 to 68 hours
Excretion	Renal (69.2%) and fecal (22.5%)
Identifiers
IUPAC name (3R)-1-Azabicyclo[2 2 2]oct-3-yl (1S)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate
Synonyms	YM905
CAS Number	242478-37-1 N
PubChem CID	154059
IUPHAR/BPS	7483
DrugBank	DB01591 Y
ChemSpider	135771 N
UNII	A8910SQJ1U
KEGG	DG00481 N
ChEMBL	CHEMBL1734 N
Chemical and physical data
Formula	C23H26N2O2
Molar mass	362.465 g/mol
3D model (JSmol)	Interactive image
SMILES C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5
InChI InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1 N Key:FBOUYBDGKBSUES-VXKWHMMOSA-N N
NY (what is this?)

Solifenacin (INN, trade name Vesicare) is a medicine of the antimuscarinic class and was developed for treating contraction of overactive bladder with associated problems such as increased urination frequency and urge incontinence. It is manufactured and marketed by Astellas, GlaxoSmithKline and Teva Pharmaceutical Industries.

Solifenacin is contraindicated for people with urinary retention, gastric retention, uncontrolled or poorly controlled closed-angle glaucoma, severe liver disease (Child-Pugh class C), and hemodialysis.

Long QT syndrome is not a contraindication although solifenacin, like tolterodine and darifenacin, binds to hERG channels of the heart and may prolong the QT interval. This mechanism appears to be seldom clinically relevant.

The most common side effects of solifenacin are dry mouth, blurred vision, and constipation. As all anticholinergics, solifenacin may rarely cause hyperthermia due to decreased perspiration.

Solifenacin is metabolized in the liver by the enzyme CYP3A4. When administered concomitantly with drugs that inhibit CYP3A4, such as , the metabolism of solifenacin is impaired, leading to an increase in its concentration in the body and a reduction in its excretion.